Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Broader off-label coverage under Part D

Executive Summary

Sens. Dianne Feinstein, D-Calif., and Sam Brownback, R-Kan., urge broader access to off-label indications under Medicare Part D in a May 22 letter to the Senate Finance Committee. The senators, who co-chair the Senate Cancer Coalition, urge that Medicare legislation being drafted by the committee include a provision allowing Part D plans to consider the "full range" of evidence in making off-label coverage decisions and bring reimbursement standards for Part D "into line with coverage standards used under Medicare Part B and by commercial insurers." CMS is currently reviewing appropriate compendia for off-label coverage under Part B (1"The Pink Sheet," April 14, 2008, p. 15)

You may also be interested in...

CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July

CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts